[{"id":"b2c74ab4-c1bb-4e58-a7dd-cb64d3bac04a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05651269","created_at":"2022-12-15T15:58:36.795Z","updated_at":"2024-07-02T16:35:59.048Z","phase":"Phase 2","brief_title":"Milciclib in Combination With Gemcitabine in Advanced NSCLC","source_id_and_acronym":"NCT05651269","lead_sponsor":"Tiziana Life Sciences LTD","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G13D • KRAS G12A • KRAS G12 • KRAS G12S • KRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • milciclib (TZLS-201)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-12-15"}]